Tegileridine
Tegileridine, sold under the brand name Aisute, is a drug which acts as a μ-opioid receptor agonist. It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G protein signalling pathway over β-arrestin2 recruitment.
In January 2024, tegileridine was approved in China under the brand name Aisute for the treatment of moderate to severe pain after abdominal surgery.